Menu

Markets

Research

News

Learn
Paper trading
AI Chat
WatchlistsPortfoliosAlerts
Sign in
Advertisement

PLSE

Pulse Biosciences, Inc.

Healthcare · USD

Set alert

Price alert · PLSE

All alert types
52.24 USD -3.24 -5.84%
As of Oct 30, 2026 Extended hours 52.00 -0.46%
Bid
52.20 × 2
Ask
52.24 × 2
51.39 Day range 54.70
12.66 52-week range 55.48
YTD
+280.48%
1 year
+209.11%
Open
54.33
Prev close
55.48
Mkt cap
3.73B
Vol
466.45K
Avg vol
500.48K
EPS
-1.18
P/E
0.00
Div yield
0.00%
More statistics
Low
51.39
High
54.70
Forward P/E
-44.65
Beta
1.57
Short ratio
5.88
Inst. own
15.32%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
50.99
200-d avg
31.16
1y target
62.33

5D chart

Chart tools
Interval
1m5m15m30m
PLSE five-day price chart52.153.254.355.456.5Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Financials
Market cap
3.73B
Enterprise value
3.86B
Trailing P/E
0.00
Forward P/E
-44.65
PEG ratio
0.00
Price / sales
3144.21
Price / book
37.18
EPS (TTM)
-1.18
Beta
1.57
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
0.00%
Revenue (TTM)
1.19M
Revenue growth
0.00%
Free cash flow
-34.29M
Total cash
101.62M
Total debt
6.77M
Return on equity
-78.49%
Shares outstanding
71.32M
Short % of float
14.09%
50-day average
50.99
200-day average
31.16

Analyst view

Consensus: none

Price target (mean) 62.33 +19.3% upside
Target (low)
55.00
Target (mean)
62.33
Target (high)
73.00
Ratings (0m) 6 6 buy · 0 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold0
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.2875.

Earnings history

Financials — quick view

All financials
PLSE Revenue — quarterly 434.00K
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PLSE Net income — quarterly -24.66M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
PLSE EPS — quarterly -0.36
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

PLSE recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.3095———
Aug 6, 2026Jun 30, 2026-0.31-0.36-0.05-16.13%
May 4, 2026Mar 31, 2026-0.32-0.27+0.05+15.62%
Feb 19, 2026Dec 31, 2025-0.265-0.26+0.01+1.89%
Nov 5, 2025Sep 30, 2025-0.31-0.29+0.02+6.45%
Aug 12, 2025Jun 30, 2025-0.26-0.28-0.02-7.69%

Upgrades / downgrades

PLSE analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026OppenheimermainOutperformOutperform
Oct 6, 2026Canaccord GenuitymainBuyBuy
Sep 23, 2026BTIGinit—Buy
Sep 9, 2026Freedom Capital Marketsinit—Buy
Aug 17, 2026Needhaminit—Buy
Aug 10, 2026Canaccord GenuitymainBuyBuy

About Pulse Biosciences, Inc.

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac Catheter System designed to provide a circumferential, or circular, ablation in a single treatment cycle; and nPulse Console, a software-enabled console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Sector
Healthcare
Industry
Medical Instruments & Supplies
Country
United States
Website
pulsebiosciences.com

News

All news

Your note

Sign in to keep a note on PLSE — it syncs with the Stock Master app.

Insider holders

PLSE insider holders
InsiderRelationLatest transactionDateShares held
BARRETT BURKE TFormerSaleDec 10, 202463,172
DANAHY KEVIN PATRICKOfficerConversion of Exercise of derivative securityFeb 17, 202643,298
DUGGAN ROBERT WILLIAMDirector and Beneficial Owner of more than 10% of a Class of SecurityPurchaseMay 10, 202649,291,700
LAVIOLETTE PAUL AChief Executive OfficerPurchaseMay 10, 202615,846
UECKER DARRIN RChief Technology OfficerConversion of Exercise of derivative securitySep 16, 2025284,406
ZANGANEH MAHKAMDirectorConversion of Exercise of derivative securityFeb 2, 2025873,469

Institution ownership

PLSE institution ownership
Holder% heldSharesValueReported
Blackrock Inc.2.07%1,466,70276.62MJun 29, 2026
Bank of America Corporation2.04%1,446,61175.57MJun 29, 2026
Vanguard Capital Management LLC1.11%788,64041.20MJun 29, 2026
Portolan Capital Management, LLC1.06%753,33339.35MJun 29, 2026
Price (T.Rowe) Associates Inc1.06%748,63839.11MJun 29, 2026
Balyasny Asset Management LP1.01%718,10337.51MJun 29, 2026

Fund ownership

PLSE fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund0.78%554,61228.97MJun 29, 2026
T. Rowe Price New Horizons Fund, Inc.0.69%485,30025.35MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF0.69%489,64325.58MSep 29, 2026
Fidelity Rutland Square TRT II-Strategic Advisers U.S. Total Stock Fd.0.49%343,54217.95MAug 30, 2026
MFS SERIES TRUST I-MFS New Discovery Fund0.48%339,45317.73MAug 30, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.30%215,88011.28MJun 29, 2026
Advertisement